| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgical Oncology (TMB, DBH, MEJ, APD, JNV, JEL, PWTP, DBE), Biostatistics (KRH), Pathology (KRC), Gastrointestinal Oncology (RAW, JLA), and Radiation Oncology (NAJ, CHC), The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Correspondence: Address correspondence and reprint requests to: Douglas B. Evans, MD, Department of Surgical Oncology, Box 444, UT M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030; Fax: 713-745-4426; E-mail: devans{at}mdanderson.org
Background: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy. The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors, and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head.
Methods: Data on 132 consecutive patients who received preoperative chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head between June 1990 and June 1999 were retrieved from a prospective pancreatic tumor database. Patients received either 45.0 or 50.4 Gy radiation at 1.8 Gy per fraction in 28 fractions or 30.0 Gy at 3.0 Gy per fraction in 10 fractions with concomitant infusional chemotherapy (5-fluorouracil, paclitaxel, or gemcitabine). If restaging studies demonstrated no evidence of disease progression, patients underwent pancreaticoduodenectomy. All patients were evaluated with serial postoperative computed tomography scans to document first sites of tumor recurrence.
Results: The overall median survival from the time of tissue diagnosis was 21 months (range 19–26, 95%CI). At last follow-up, 41 patients (31%) were alive with no clinical or radiographic evidence of disease. The survival duration was superior for women (P = .04) and for patients with no evidence of lymph node metastasis (P = .03). There was no difference in survival duration associated with patient age, dose of preoperative radiation therapy, the delivery of intraoperative radiotherapy, tumor grade, tumor size, retroperitoneal margin status, or the histologic grade of chemoradiation treatment effect.
Conclusion: This analysis supports prior studies which suggest that the survival duration of patients with potentially resectable pancreatic cancer is maximized by the combination of chemoradiation and pancreaticoduodenectomy. Furthermore, there was no difference in survival duration between patients who received the less toxic rapid-fractionation chemoradiotherapy schedule (30 Gy, 2 weeks) and those who received standard-fractionation chemoradiotherapy (50.4 Gy, 5.5 weeks). Short-course rapid-fractionation preoperative chemoradiotherapy combined with pancreaticoduodenectomy, when performed on accurately staged patients, maximizes survival duration and is associated with a low incidence of local tumor recurrence.
Key Words: Pancreaticoduodenectomy • Pancreatic cancer • Chemoradiation
This article has been cited by other articles:
 |
|
 |
|
  T. B. Brunner, M. Geiger, G. G. Grabenbauer, M. Lang-Welzenbach, T. S. Mantoni, A. Cavallaro, R. Sauer, W. Hohenberger, and W. G. McKenna Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer J. Clin. Oncol., June 1, 2008; 26(16): 2699 - 2706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Heinrich, B. C. Pestalozzi, M. Schafer, A. Weber, P. Bauerfeind, A. Knuth, and P.-A. Clavien Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head J. Clin. Oncol., May 20, 2008; 26(15): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Small Jr, J. Berlin, G. M. Freedman, T. Lawrence, M. S. Talamonti, M. F. Mulcahy, A. B. Chakravarthy, A. A. Konski, M. M. Zalupski, P. A. Philip, et al. Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial J. Clin. Oncol., February 20, 2008; 26(6): 942 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. G. Katz, R. Hwang, J. B. Fleming, and D. B. Evans Tumor-Node-Metastasis Staging of Pancreatic Adenocarcinoma CA Cancer J Clin, February 13, 2008; (2008) CA.2007.0012v1. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. B. Slidell, D. C. Chang, J. L. Cameron, C. Wolfgang, J. M. Herman, R. D. Schulick, M. A. Choti, and T. M. Pawlik Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis Ann. Surg. Oncol., January 1, 2008; 15(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Mansour, L. Tang, M. Shah, D. Bentrem, D. S. Klimstra, M. Gonen, D. P. Kelsen, M. F. Brennan, and D. G. Coit Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer? Ann. Surg. Oncol., December 1, 2007; 14(12): 3412 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Palmer, D. D. Stocken, H. Hewitt, C. E. Markham, A. B. Hassan, P. J. Johnson, J. A. C. Buckels, and S. R. Bramhall A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin Ann. Surg. Oncol., July 1, 2007; 14(7): 2088 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. White, M. W. Kattan, J. C. Haney, B. M. Clary, T. N. Pappas, D. S. Tyler, and M. F. Brennan Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nomogram Ann. Surg. Oncol., November 1, 2006; 13(11): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Massucco, L. Capussotti, A. Magnino, E. Sperti, M. Gatti, A. Muratore, E. Sgotto, P. Gabriele, and M. Aglietta Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival Ann. Surg. Oncol., September 1, 2006; 13(9): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Varadhachary, E. P. Tamm, J. L. Abbruzzese, H. Q. Xiong, C. H. Crane, H. Wang, J. E. Lee, P. W. T. Pisters, D. B. Evans, and R. A. Wolff Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy Ann. Surg. Oncol., August 1, 2006; 13(8): 1035 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Raut, K. R. Cleary, G. A. Staerkel, J. L. Abbruzzese, R. A. Wolff, J. H. Lee, J.-N. Vauthey, J. E. Lee, P. W. T. Pisters, and D. B. Evans Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival Ann. Surg. Oncol., April 1, 2006; 13(4): 582 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-Y. Cheng, K. Sheth, R. R. White, T. Ueno, C.-F. Hung, B. M. Clary, T. N. Pappas, and D. S. Tyler Effect of Neoadjuvant Chemoradiation on Operative Mortality and Morbidity for Pancreaticoduodenectomy Ann. Surg. Oncol., January 1, 2006; 13(1): 66 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y. Yang, T. D. Wagner, M. Fuss, and C. R. Thomas Jr. Multimodality Approaches for Pancreatic Cancer CA Cancer J Clin, November 1, 2005; 55(6): 352 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ohigashi, O. Ishikawa, H. Eguchi, Y. Sasaki, T. Yamada, S. Noura, K. Murata, K. Takachi, I. Miyashiro, Y. Doki, et al. Feasibility and Efficacy of Combination Therapy With Preoperative and Postoperative Chemoradiation, Extended Pancreatectomy, and Postoperative Liver Perfusion Chemotherapy for Locally Advanced Cancers of the Pancreatic Head Ann. Surg. Oncol., August 1, 2005; 12(8): 629 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Chua and D. Cunningham Adjuvant Treatment for Resectable Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4532 - 4537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Pancreatic Section Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas Gut, June 1, 2005; 54(suppl_5): v1 - v16. [Full Text] [PDF]
|
|
|
|
|
|
R. R. White, H. B. Xie, M. R. Gottfried, B. G. Czito, H. I. Hurwitz, M. A. Morse, G. C. Blobe, E. K. Paulson, J. Baillie, M. S. Branch, et al. Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer Ann. Surg. Oncol., March 1, 2005; 12(3): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Sclabas, S. Fujioka, C. Schmidt, Z. Li, W. A.I. Frederick, W. Yang, K. Yokoi, D. B. Evans, J. L. Abbruzzese, K. R. Hess, et al. Overexpression of Tropomysin-Related Kinase B in Metastatic Human Pancreatic Cancer Cells Clin. Cancer Res., January 15, 2005; 11(2): 440 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Morris, M. Beasley, M. Leslie, C. H. Crane, E. Ben-Josef, W. Small Jr., S. Bydder, N. Spry, J. P. Neoptolemos, D. Stocken, et al. Chemotherapy for Pancreatic Cancer N. Engl. J. Med., June 24, 2004; 350(26): 2713 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Niu, Z. Li, B. Peng, and P. J. Chiao Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1{alpha} in Induction of Constitutive NF-{kappa}B Activation in Pancreatic Cancer Cells J. Biol. Chem., April 16, 2004; 279(16): 16452 - 16462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Katz, D. E. Spivack, S. Takimoto, B. Fang, D. W. Burton, A.R. Moossa, R. M. Hoffman, and M. Bouvet Gene Therapy of Pancreatic Cancer With Green Fluorescent Protein and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Gene Expression Driven by a Human Telomerase Reverse Transcriptase Promoter Ann. Surg. Oncol., August 1, 2003; 10(7): 762 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Neoptolemos, D. Cunningham, H. Friess, C. Bassi, D. D. Stocken, D. M. Tait, J. A. Dunn, C. Dervenis, F. Lacaine, H. Hickey, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives Ann. Onc., May 1, 2003; 14(5): 675 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fujioka, G. M. Sclabas, C. Schmidt, W. A. Frederick, Q. G. Dong, J. L. Abbruzzese, D. B. Evans, C. Baker, and P. J. Chiao Function of Nuclear Factor {kappa}B in Pancreatic Cancer Metastasis Clin. Cancer Res., January 1, 2003; 9(1): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Kim, M.-J. Kim, J.-J. Chung, W. J. Lee, H. S. Yoo, and J. T. Lee Differential Diagnosis of Periampullary Carcinomas at MR Imaging RadioGraphics, November 1, 2002; 22(6): 1335 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. T. Pisters, R. A. Wolff, N. A. Janjan, K. R. Cleary, C. Charnsangavej, C. N. Crane, R. Lenzi, J. Nicolas Vauthey, J. E. Lee, J. L. Abbruzzese, et al. Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome J. Clin. Oncol., May 15, 2002; 20(10): 2537 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Wayne, E. K. Abdalla, R. A. Wolff, C. H. Crane, P. W.T. Pisters, and D. B. Evans Localized Adenocarcinoma of the Pancreas: The Rationale for Preoperative Chemoradiation Oncologist, February 1, 2002; 7(1): 34 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. White, H. I. Hurwitz, M. A. Morse, C. Lee, M. S. Anscher, E. K. Paulson, M. R. Gottfried, J. Baillie, M. S. Branch, P. S. Jowell, et al. Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas Ann. Surg. Oncol., December 1, 2001; 8(10): 758 - 765. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
